Incyte Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| INCY | 6IB.F | 9969.HK | IOVA | GMAB | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | 25.04B | 17.27B | 21.56B | 3.94B | 33.89B | 37.99B |
| P/E (TTM) | 62.7 | 123.8 | 20.3 | — | 43.4 | 4.1 |
| Forward P/E | 14.2 | — | 53.2 | -44.4 | 34.9 | 11.2 |
| Price/book | 4.4 | 6.2 | 1.9 | 5.4 | 5.5 | 1.2 |
| Dividend yield | — | — | — | — | — | 1.69% |
| 1-year change | +16.78% | −1.76% | −14.61% | +276.62% | +91.12% | −51.32% |
| Today | +4.47% | +3.42% | +1.33% | −1.47% | −0.72% | +4.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All INCY news ›IDEAYA Biosciences (NASDAQ:IDYA) Given New $52.00 Price Target at Guggenheim
Posted by Mitch Edgeman on Nov 4th, 2026 IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its price objective decreased by equities researchers at Guggenheim from $57.00 to $52.00 in a research report issued on Wednesday, Benzinga…
Chronic Hand Eczema Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics
Albany New York November 03 2026 As per DelveInsight s assessment globally Chronic Hand Eczema pipeline constitutes 5 key companies continuously working towards developing 5 Chronic Hand Eczema treatment therapies analysis of Clinical…
Leerink Partners Adjusts Insulet Price Target to $143 From $145
Insulet has an average rating of overweight and mean price target of $177.33, according to analysts polled by FactSet. Price: 135.87, Change: +1.40, Percent Change: +1.04 ... Medical Equipment, Supplies & Distribution Leerink Partners…
Major Depressive Disorder Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm
Major Depressive Disorder Pipeline 2026: Key Companies, MOA, openPR.com Major Depressive Disorder Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis…
Inderes lowers target price for Evli to €25 (27), reiterates accumulate
Inderes lowers target price for Evli to €25 , reiterates accumulate... Investment Management & Fund Operators Inderes lowers target price for Evli to €25 (27), reiterates accumulate
Incyte raises sales outlook as quarterly revenue reaches US$1.56B
Opzelura and hematology sales drove the forecast increase, while a US$1.23 billion acquisition charge lifted research expense. Revenue grew 14 per cent to US$1.56 billion as Incyte Corporation NASDAQINCY raised its full-year sales forecast…
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap
(NASDAQ:INCY) Seeking Alpha - I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. - ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. - Q3 net sales r
INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins
Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on year to $1.56 billion. On the other hand, the company’s full-year revenue guidance…
Inderes lowers Remedy Entertainment to Accumulate (Buy), price target €23 (21)
Inderes lowers Remedy Entertainment to Accumulate , price target €23 ... Inderes lowers Remedy Entertainment to Accumulate (Buy), price target €23 (21) Published on 09/28/2026 at 12:04 am EDT Latest news about Remedy Entertainment Oyj…
Incyte Corporation $INCY Stock: Profund Advisors LLC Raises Stake
Posted by Michael Walen on Nov 2nd, 2026 Here are the key news stories impacting Incyte this week: INCY stock opened at $120.39 on Monday. The company has a market cap of $24.54 billion, a P/E ratio of 64.04, a price-to-earnings-growth…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com12
- themarketsdaily.com8
- theglobeandmail.com7
- seekingalpha.com5
- forbes.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 72 articles, not a forecast.